ArticleJournal of tissue engineering and regenerative medicine2022
Selective kidney targeting increases the efficacy of mesenchymal stromal/stem cells for alleviation of murine stenotic-kidney senescence and damage.
Article in Journal of tissue engineering and regenerative medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Targeting cellular senescence in diabetic kidney disease: potential of regenerative, cell-based therapies and other senotherapeutic approaches.Kidney international · 2026Review
- Obesity exacerbates ischemia-reperfusion injury and senescence in murine kidneys and perirenal adipose tissues.Kidney research and clinical practice · 2025Article
- Cellular senescence in renal ischemia-reperfusion injury.Chinese medical journal · 2025Review
- Understanding and targeting senescence in kidney disease.Clinical kidney journal · 2025Review
- Targeting cellular senescence in kidney diseases and aging: A focus on mesenchymal stem cells and their paracrine factors.Cell communication and signaling : CCS · 2024Review
- Targeted therapeutic strategies for the kidney.Expert opinion on therapeutic targets · 2024Review
- Kidney Aging and Chronic Kidney Disease.International journal of molecular sciences · 2024Review
- Astragalus polysaccharides augment BMSC homing via SDF-1/CXCR4 modulation: a novel approach to counteract peritoneal mesenchymal transformation and fibrosis.BMC complementary medicine and therapies · 2024Article
- Kidney Intrinsic Mechanisms as Novel Targets in Renovascular Hypertension.Hypertension (Dallas, Tex. : 1979) · 2024Review
- Human liver derived mesenchymal stromal cells ameliorate murine ischemia-induced inflammation through macrophage polarization.Frontiers in immunology · 2024Article
- Cellular senescence in ischemia/reperfusion injury.Cell death discovery · 2022Review
- Cerebral Microvascular Senescence and Inflammation in Diabetes.Frontiers in physiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Chronic ischemia triggers senescence in renal tubules and at least partly mediates kidney dysfunction and damage through a p16
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.